Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus
Ahmed, S. F.; Sohail, M. S.; Quadeer, A. A.; McKay, M. R.
Show abstract
Starting May 2022, a novel cluster of monkeypox virus infections was detected in humans. This has spread rapidly to non-endemic countries and sparked global concern. Vaccinia virus vaccines have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variation that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates vaccine-induced immune responses to remain highly cross-reactive against the newly observed monkeypox viruses.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Future Sequon Finder - A novel approach for predicting future N-linked glycosylation sequons on viral surface proteins 95%
- Brief report: Mutations in SIV Nef that disrupt and restore tetherin downregulation 94%
- Genotype-matched Newcastle disease virus vaccine confers improved protection against genotype XII challenge: The importance of cytoplasmic tails in viral replication and vaccine design 94%
Similar papers in this journal
Similar papers in this journal
- Emergence and spread of the potential variant of interest (VOI) B.1.1.519 predominantly present in Mexico 94%
- Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein 94%
- Taxonomic classification methods reveal a new subgenus in the paramyxovirus subfamily Orthoparamyxovirinae 94%
Similar papers in this journal
- Immunodominant and neutralizing linear B cell epitopes spanning the spike and membrane proteins of Porcine Epidemic Diarrhea Virus 95%
- Pox-AbDab: the Orthopoxvirus Antibody Database 93%
- Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.